SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-21-110517
Filing Date
2021-08-27
Accepted
2021-08-27 16:08:02
Documents
16
Period of Report
2021-08-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2125838d2_8k.htm   iXBRL 8-K 34129
2 EXHIBIT 1.1 tm2125838d2_ex1-1.htm EX-1.1 254172
3 EXHIBIT 5.1 tm2125838d2_ex5-1.htm EX-5.1 7990
7 GRAPHIC tm2125838d2_ex5-1img001.jpg GRAPHIC 21987
8 GRAPHIC tm2125838d2_ex5-1img002.jpg GRAPHIC 2653
  Complete submission text file 0001104659-21-110517.txt   571369

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA ettx-20210826.xsd EX-101.SCH 3191
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE ettx-20210826_lab.xml EX-101.LAB 34593
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ettx-20210826_pre.xml EX-101.PRE 22714
9 EXTRACTED XBRL INSTANCE DOCUMENT tm2125838d2_8k_htm.xml XML 3615
Mailing Address 35 GATEHOUSE DRIVE WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE WALTHAM MA 02451 (781) 810-0120
Entasis Therapeutics Holdings Inc. (Filer) CIK: 0001724344 (see all company filings)

IRS No.: 824592913 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38670 | Film No.: 211218960
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences